Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
AstraZeneca released new results from the company’s ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC), after complete tumor resection.
The U.S. Food and Drug Administration approved Roche’s Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion’s Soliris in a costly treatment area.
Seattle-based Athira Pharma closed on a Series B financing worth $85 million, led by Perceptive Advisors.
Kallyope, based in the Alexandria Center for Life Science in New York City, secured $112 million in a Series C financing round that will be used to advance the company’s gut-brain axis field-focused programs into clinical trials.
Roche company Genentech announced that the Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy did not hit the primary endpoint in muscle-invasive urothelial cancer (MIUC).
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
Novartis, Amgen and the Banner Alzheimer’s Institute announced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.